Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

Post hoc analysis found higher baseline lipoprotein(a) levels were associated with greater reduction in total cardiovascular events with alirocumab (P=0.045). Each 5-mg/dL reduction in lipoprotein(a) predicted a 2.5% relative reduction in cardiovascular events.

Source:

European Heart Journal